Guidelines for the use of extended-release nevirapine in HIV-infected patients

Bibliography

• Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;12:1296-310
   Google Scholar
• Rosenbach KA, Allison R, Nadler JP. Daily dosing of highly active antiretroviral therapy. Clin Infect Dis 2002;34:686-92
   PubMed Web of Science ®Google Scholar
• Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2011. Available from: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf [Last accessed 18 October 2011]
   Google Scholar
• van Leth F, Phanuphak P, Ruxrungtham K, Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 2004;363:1253-63
   PubMed Web of Science ®Google Scholar
• Towner W, Kerrigan HL, LaRiviere M. Efficacy of a once-daily (QD) regimen of nevirapine (NVP), lamivudine (3TC) and tenofovir (TDF) in treatment-naive HIV infected patients: a pilot study. Presented at the 7th International Congress on Drug Therapy in HIV Infection; 14 – 17 November 2004; Glasgow, Scotland
   Google Scholar
• Rey D, Hoen B, Chavanet P, High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients. J Antimicrob Chemother 2009;63:380-8
   PubMed Web of Science ®Google Scholar
• Lapadula G, Costarelli S, Quiros-Roldan E, Risk of early virological failure of once-daily tenofovir-emtricitabine plus twice-daily nevirapine in antiretroviral therapy-naive HIV-infected patients. Clin Infect Dis 2008;46:1127-9
   PubMed Web of Science ®Google Scholar
• Soriano V, Arasteh K, Migrone H, Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN trial. Antivir Ther 2011;16:339-48
   PubMed Web of Science ®Google Scholar
• Department of Health and Human Services Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. 2011. Available from: http://aidsinfo.nih.gov/ContentFiles/PerinatalGL.pdf [Last accessed 18 October 2011]
   Google Scholar
• Boehringer Ingelheim Pharmaceuticals, Inc. Viramune prescribing information. 2011. Available from: http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing+Information/PIs/Viramune/Viramune.pdf [Last accessed 30 June 2011]
   Google Scholar
• Boehringer Ingelheim Pharmaceuticals, Inc. Viramune XR prescribing information. 2011. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/201152s000lbl.pdf [Last accessed 30 June 2011]
   Google Scholar
• Gathe J, Andrade-Villanueva J, Santiago S, Efficacy and safety of nevirapine extended-release once daily versus nevirapine immediate-release twice-daily in treatment-naive HIV-1 infected patients. Antivir Ther 2011;16(5):759-69
   PubMed Web of Science ®Google Scholar
• Arasteh K. 24-week efficacy and safety of transitioning virologically stable HIV-1 patients from IR nevirapine 200 mg BID to nevirapine XR 400 mg QD. Presented at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 12 – 15 September 2010; Boston, MA, USA
   Google Scholar
• Arasteh K. 48-week efficacy and safety of switching virologically stable HIV-1 patients from nevirapine IR 200 mg BID to nevirapine XR 400 mg QD (TRANxITION). Presented at the 10th International Congress on Drug Therapy in HIV Infection; 7 – 11 November 2010; Glasgow, Scotland
   Google Scholar
• Battegay M, Arasteh K, Plettenberg A, Bioavailability of extended-release nevirapine 400 and 300 mg in HIV-1: a multicenter, open-label study. Clin Ther 2011;33:1308-20
   Google Scholar
• Boehringer Ingleheim Pharmaceuticals, Inc. Study 1100:1486: Phase III study comparing nevirapine XR 400 mg QD vs IR 200 mg BID for 48 weeks, including a PK substudy at week 4. Data on File with Boehringer Ingelheim. 2010
   Google Scholar
• Boehringer Ingleheim Pharmaceuticals, Inc. Study 1100: 1526: Open-label Phase III study comparing nevirapine XR 400 mg QD vs IR 200 mg BID in patients pretreated with nevirapine IR 200 mg BID. Data on File with Boehringer Ingelheim. 2011
   Google Scholar
• de Vries-Sluijs TE, Dieleman JP, Arts D, Low nevirapine plasma concentrations predict virological failure in an unselected HIV-1-infected population. Clin Pharmacokinet 2003;42:599-605
   PubMed Web of Science ®Google Scholar